Safety of nateglinide as used in general practice in England: Results of a prescription-event monitoring study

Acta Diabetologica

Volumn 44, Issue 4, 2007, Pages 233-239

  Twaites, B ^a   Wilton, L V ^a,b   Layton, D ^a,b   Shakir, S A W ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Drug safety; Nateglinide; Post marketing surveillance; Prescription event monitoring; Type 2 diabetes

Indexed keywords

ATORVASTATIN; METFORMIN; NATEGLINIDE;

ABDOMINAL PAIN; ADULT; AGED; AIRWAY OBSTRUCTION; ANGIONEUROTIC EDEMA; ANOREXIA; ARTICLE; BACTERIAL INFECTION; BIRTH DEFECT; COHORT ANALYSIS; COUGHING; DIARRHEA; DIZZINESS; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EDEMA; FEMALE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GENERAL PRACTICE; HEART PALPITATION; HUMAN; HYPOGLYCEMIA; INCREASED APPETITE; LASSITUDE; MALAISE; MALE; MIGRAINE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICIAN; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RASH; RAYNAUD PHENOMENON; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SKIN INFECTION; SKIN PRURITUS; TREATMENT WITHDRAWAL; TREMOR; UNITED KINGDOM; VAGINITIS; VOMITING; VULVITIS; WEIGHT GAIN;

AGED; CONFIDENTIALITY; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; ENGLAND; FAMILY PRACTICE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PHENYLALANINE; PRESCRIPTIONS, DRUG; SAFETY;

EID: 36248952778     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-007-0010-y     Document Type: Article

References (15)

1. Shinkai H, Toi K, Kumashiro I, Seto Y, Fukuma M, Dan K, Toyoshima S (1988) N-acylphenylalanines and related compounds. A new class of oral hypoglycaemic agents. J Med Chem 31:2092-2097
2. Nateglinide (Starlix). Summary of product characteristics. 2001. Novartis
3. Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S (2000) Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 23:1660-1665
4. Shakir S (2002) Prescription-event monitoring. In: Mann RD, Andrews E (eds) Pharmacovigilance. Wiley, Chichester
5. Shakir S (2004) Causality and correlation in pharmacovigilance. In: Talbot J, Waller P (eds) Stephens' detection of new adverse drug reactions, 5th edn. Wiley, Chichester, pp 329-343
6. CIOMS, WHO (2002) International ethical guidelines for biomedical research involving human subjects, Geneva
7. Royal College of Physicians of London (1996) Guidelines on the practice of ethics committees in medical research involving human subjects, 3. Royal College of Physicians of London
8. Multi-centre research ethics committees guidance notes (2000) Examples of enquiries and surveys in the public interest where no reference to a research ethics committee is necessary. Appendix C;21
9. Martin RM, Kapoor KV, Wilton LV et al (1998) Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study. Br Med J 317(7151):119-120
10. BUPA's Health Information Team (2005) Diabetes Type 2. Web address: http://hcd2.bupa.co.uk/fact_sheets/html/diabetes2.html
11. Patient UK (2005) Diabetes Type 2. Web address: http://www.patient.co.uk/ showdoc/23068721/
12. Williams G (1994) Management of non-insulin dependent diabetes. Lancet 343:95-100
13. Horton ES, Foley JE, Shen SG, Baron MA (2004) Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 20:883-889
14. Parke Davis (2005) Atorvastatin (Lipitor™). Summary of product characteristics, March 2005
15. Merck Pharmaceuticals (2005) Metformin (Glucophage). Summary of product characteristics, April 2005